In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.
Precision medicine has been focused on the presence of activating mutations or gene amplifications. However, recent data has shown that the presence of gene fusions also offer a unique treatment opportunity, with the potential for durable clinical responses.
Our panel will discuss several such clinical cases in detail and recommend a course of treatment based on the genomic profiles of the patients.
The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.
The Virtual Molecular Tumor Board Series is an interactive and educational online program intended to highlight the key role that molecular tumor boards play in implementing precision oncology.
The series will underscore the collaborative nature of genomic medicine by assembling a multidisciplinary panel of experts who will meet virtually for four one-hour sessions. In each session, the panel will review the genomic and clinical evidence for anonymized patients who have had their tumors sequenced as part of clinical management. The panel will discuss each case and recommend a course of treatment.
Precision Oncology News would like to thank Clariifi for assistance in planning and executing this educational webinar series.